Drug intelligence / Profile preview

ILYX-004

Development stage: Preclinical
Lead developer: Iolyx Therapeutics

Overview

ILYX-004 is an investigational therapeutic agent being developed by Iolyx Therapeutics. It is part of the company's pipeline focused on ocular conditions, specifically targeting retinal indications. Iolyx Therapeutics specializes in developing therapeutics at the intersection of ocular inflammation and autoimmunity, utilizing proprietary pathways and tailored formulations for precise delivery to relevant tissues. While specific details regarding the mechanism of action for ILYX-004 are not publicly disclosed, it is intended to address conditions affecting the retina.

Beyond the preview

Go deeper on ILYX-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILYX-004.

Explore the full profile